That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’sRatings downgraded the sovereign credit rating ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...

WHAT TO WATCH: --Novo Nordisk has been affected by uncertainty about President Trump's tariffs, disappointing trial data and prescription stagnation as a result of production challenges and ...

But I underestimated the severity of their operational challenges and both stocks ... totally corner this massive market. So I see Novo Nordisk stock as a cheap way for me to invest in this ...